tradingkey.logo

Senestech Inc

SNES
View Detailed Chart

4.900USD

-0.100-2.00%
Close 09/03, 16:00ETQuotes delayed by 15 min
18.44MMarket Cap
LossP/E TTM

Senestech Inc

4.900

-0.100-2.00%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.00%

5 Days

+3.59%

1 Month

-6.67%

6 Months

+67.81%

Year to Date

+48.04%

1 Year

+63.88%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
56 / 72
Overall Ranking
319 / 4737
Industry
Chemicals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
10.000
Target Price
+100.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 82.24% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.86M.
Overvalued
The company’s latest PE is 0.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 110.88K shares, decreasing 33.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 13.50K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.
Ticker SymbolSNES
CompanySenestech Inc
CEOMr. Joel L. Fruendt
Websitehttps://senestech.com/
KeyAI